Edgar, Christina D, Blair, Anna, Tate, Warren P · Methods in molecular biology (Clifton, N.J.) · 2025 · DOI
This study looked at variations in a specific gene called IDO2 that controls an enzyme involved in breaking down tryptophan, an amino acid in our bodies. The researchers compared how often these genetic variations appear in ME/CFS patients versus healthy people, to see if certain variations might make someone more vulnerable to developing ME/CFS after a triggering event like a viral infection. They developed a straightforward laboratory technique to identify five common mutations in this gene.
Understanding genetic variations that may predispose individuals to ME/CFS could help identify at-risk populations and advance our understanding of disease mechanisms. The tryptophan-kynurenine pathway has emerged as a potential therapeutic target in ME/CFS, making genetic variants in pathway enzymes like IDO2 clinically relevant. This work establishes reproducible methods for studying genetic contributions to ME/CFS susceptibility.
This methods paper does not present comparative frequency data or demonstrate that IDO2 variants actually cause or increase susceptibility to ME/CFS—that would require completed genetic association studies. The study does not establish causation or prove that any particular variant is pathogenic. It only describes the technical approach for identifying these genetic variations.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.